Best Oral Dutasteride Providers of 2026
Oral dutasteride offers the most potent DHT suppression of any currently available pharmacological hair loss treatment. By inhibiting both type I and type II 5-alpha reductase, it reduces DHT levels by up to 90% — outperforming finasteride in both mechanism and clinical hair count outcomes. We’ve ranked the 3 best telemedicine providers offering oral dutasteride in 2026.
Oral dutasteride for hair loss is prescribed off-label in most countries. It is FDA-approved for benign prostatic hyperplasia (BPH). A prescription and ongoing clinician monitoring are required.
What is it?
What is oral dutasteride?
Dutasteride 0.5mg is a dual-action 5-alpha reductase inhibitor approved by the FDA for BPH and widely used off-label for androgenetic alopecia. Its dual mechanism — blocking both type I and type II isoforms of the enzyme — produces greater overall DHT suppression than finasteride, with clinical trial data demonstrating superior hair count improvements across multiple studies.
A randomized controlled trial published in JAAD found dutasteride 0.5mg produced significantly greater hair count improvements than finasteride 1mg at 24 weeks , making it one of the strongest evidence-backed treatment escalations currently available for men with androgenetic alopecia.
- Suppress DHT by up to 90% — more than any other approved oral treatment
- Produce greater hair count improvements than finasteride in clinical trials
- Represent a meaningful step-up for finasteride non-responders
- Combines well with minoxidil for comprehensive coverage
Due to dutasteride’s long half-life (~5 weeks), its effects on DHT persist for months after the last dose. This makes consistency less critical on a day-to-day basis than with finasteride — but also means that any side effects take significantly longer to resolve if the medication is stopped.
- Ongoing DHT-driven follicle miniaturization without intervention
- Progressive reduction in hair density, particularly at vertex and hairline
- Permanent follicle inactivation in severely affected areas over time
- Increasing reliance on surgical options as the medical window closes
- Significant psychosocial impact associated with visible hair loss
- Reduced likelihood of meaningful pharmacological response as loss advances
What to watch out for
Common mistakes when choosing an oral dutasteride provider.
Not using the clinically-validated softgel form
All major clinical trials of oral dutasteride have used a fully-emulsified softgel formulation. Compounded alternatives in powder capsule or tablet form have not been validated by clinical research.
Not disclosing blood donation plans
Men taking dutasteride must not donate blood for at least six months after the last dose, due to the risk of the medication reaching a pregnant female recipient.
Ignoring PSA implications
Dutasteride significantly suppresses PSA levels. Men with any prostate health monitoring in place must inform their urologist or GP before starting dutasteride.
Underestimating the half-life
Dutasteride’s ~5-week half-life means side effects — including any sexual effects — persist for months after stopping. This is a meaningful clinical consideration that should be discussed before prescribing.
Dosage & forms
How oral dutasteride is prescribed.
Standard 0.5mg capsule
The FDA-approved dose for BPH — and the most studied dose for hair loss. Widely available through compounding pharmacies and select telehealth platforms.
Most commonLow-dose dutasteride
Some clinicians prescribe lower doses (e.g., 0.1mg or every other day) to reduce the systemic DHT burden while maintaining some therapeutic effect.
Off-labelCombination with minoxidil
Oral dutasteride is frequently paired with minoxidil for a comprehensive approach — one targeting DHT, the other stimulating follicle activity directly.
RecommendedCompounded formulations
Some providers offer dutasteride in custom concentrations or alongside other actives for a fully tailored treatment plan.
Provider-specificRanked
Top 3 Oral Dutasteride Providers of 2026
Rankings based on clinical credibility, off-label prescribing experience, monitoring, personalization, and pricing transparency.
At a glance: how they compare
| Product |
Ulo
|
Musely
|
Happy Head
|
| Clinically-studied softgel form | |||
| Prescription required | |||
| 0.5mg clinical trial dose | |||
| Physician / dermatologist oversight | |||
| Minoxidil combination available | |||
| Transparent pricing |
Ulo is the only telehealth provider in this review that offers oral dutasteride exclusively in its clinically-studied, fully-emulsified softgel form. All clinical trial data for oral dutasteride is based on this formulation, which uses a lipid-based delivery system to maximise bioavailability. Ulo does not compound dutasteride into powder capsules or combined tablets, which can compromise absorption and diverge from the studied dose form. Board-certified physician oversight is included throughout.
Musely offers oral dutasteride as part of their Hair Pill, a compounded prescription formulation combining dutasteride (0.4mg) with minoxidil (1mg or 2mg) in a single capsule. The low monthly cost and multi-ingredient approach make it one of the more accessible entry points for oral dutasteride. Board-certified dermatologists conduct the initial onboarding consultation, but follow-up is sparse.
Happy Head offers oral dutasteride (0.5mg) under dermatologist supervision, with the option to upgrade to their SuperCapsule, a combination pill containing dutasteride (0.5mg), oral minoxidil (1.25mg), and vitamin D3 (2,000 IU). Dermatologist oversight is available throughout the treatment process, and delivery is offered across most US states.
FAQs
Frequently asked questions.
Get started
Not sure where to start?
We’ll point you to the approach and products best suited to your profile.
- Gubelin Harcha W et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70(3):489–498.
- Olsen EA et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014–1023.
- Ding Y et al. Dutasteride for the Treatment of Androgenetic Alopecia: An Updated Review. Dermatology. 2024;240(5–6):833–843.
- Fertig RM et al. Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review. Dermatol Online J. 2017;23(11).
- Chung HC et al. Long-term efficacy and safety of the dual 5-alpha reductase blocker dutasteride on male androgenetic alopecia patients. J Dermatol. 2017;44(12):1408–1409.